Ix Therapeutics GmbH

Biotech and Therapies

Description

The iX Therapeuthics GmbH is a joint venture company founded by Xlife Sciences AG and Indivumed GmbH in March 2021. The company has its registered seat in Hamburg, Germany.

Ix Therapeutics GmbH is intended to use Indivumed’s AI-based platform nRavel®, which, together with Indivumed’s IndivuType multi-omics database, is intended to deliver more precise insights into and much better predictors for certain pathologies and diseases with high medical needs. The IndivuType database is a combinedcollection of high-quality multi-omics and accompanying clinical data from thousands of cancer patients combined with whole genome sequencing, transcriptomics, proteomics, and phosphoproteomics data. Ix Therapeutics GmbH uses the technology platform of Veraxa Biotech AG for the development of antibodies with the aim to discover modulatory and functional antibodies against several targets relevant for colorectal cancer that have been identified by Indivumed’s nRavel® platform. The collaboration opens new possibilities for cancer treatment. The combined technologies target the effective development of functional precision antibodies against cancer for an individualized cancer therapy.

For more information, please visit: www.ix-therapeutics.com

Melden Sie sich für unsere Medienmitteilungen an

Wir berichten regelmässig über die geschäftliche Entwicklung der Xlife Sciences AG und unserer Projektgesellschaften.